Loading…
Employees: 174
Size Anteris Technologies Global (AVR) is a United States Health Care company (Medical Specialties) with a market value of $555M, the 2624th largest of 3,117 United States companies the cockpit tracks. Shares closed at $5.69 on 6 Nov 2026.
Performance Over six months the shares fell 13.5%, against -10.3% for the median peer and -1.1% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue fell 9.6% over the last twelve months (peer median +5.8%); the operating margin is -4,738.4% (peer median 2.7%).
Valuation It trades at 2.20× book value against a peer median of 2.00× (9th most expensive of 19).
Price implies The share price implies a return on equity of about 29.3%; Anteris Technologies Global delivers -75.1%, so the price asks more than the business earns today.
Short interest Short interest is 8.1% of the free float (15 Oct 2026).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.24M | $1.91M | $2.70M | $2.73M | $3.20M |
| Revenue growth | — | -29% | -1% | -15% | — |
| Gross profit | -$57,000 | -$317,000 | -$241,000 | -$280,923 | -$475,694 |
| EBITDA | -$104M | -$92.2M | -$76.9M | -$46.2M | -$32.0M |
| Net income | -$104M | -$94.1M | -$76.3M | -$46.0M | -$30.6M |
| Free cash flow | -$88.2M | -$79.8M | -$63.5M | -$37.0M | -$31.0M |
| Capital expenditure | $2.00M | $1.95M | $2.28M | $2.39M | $1.67M |
| Total debt | $3.32M | $2.28M | $1.40M | $1.69M | $952,787 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AVR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.2% | -0.7% | 3rd lowest of 20 |
| 6-month return | -13.5% | -10.3% | 9th lowest of 20 |
| Return on equity | -75.1% | 2.4% | lowest of 19 |
| Price / book | 2.20× | 2.00× | 9th most expensive of 19 |
| ROE the price implies | 29.3% | 19.2% | 4th most demanding of 19 |
| ROE delivered | -75.1% | 1.8% | lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -75% | 2.20× | 29.3% | -75.1% |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -48% | 10.43× | 149.1% | -48.4% |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 3% | 1.22× | 8.3% | 3.4% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -11% | 0.62× | 5.7% | -10.9% |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 27% | 4.82× | 84.3% | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 9% | 2.13× | 23.4% | 9.5% |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -33% | 1.86× | 21.6% | -32.5% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 16% | 4.17× | 20.2% | 15.8% |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 2% | 0.94× | 5.4% | 1.8% |
| Assure Tech (Hangzhou) 688075.SS | China | $538M | -25% | -21% | 0% | 0.71× | 6.7% | 0.0% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 1% | 1.46× | 12.7% | 1.1% |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 0% | 1.02× | 6.5% | 0.0% |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 4% | 0.87× | 17.6% | 4.0% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 4% | 2.22× | 19.1% | 4.1% |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 11% | 2.58× | 20.1% | 11.0% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 3% | 0.88× | 5.6% | 3.0% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | 3.10× | 19.3% | -9.1% |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | 0% | 4.27× | 24.1% | 0.5% |
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 8% | 3.97× | 34.4% | 8.3% |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | n/a | n/a | n/a | n/a |